Epithelium-On Corneal Cross-linking in Subjects 8 to 45 Years of Age with Keratoconus
(Apricity-B Trial)
Recruiting at 12 trial locations
MB
Overseen ByMichael Belin, MD
Age: < 65
Sex: Any
Trial Phase: Phase 3
Sponsor: Epion Therapeutics
Pivotal Trial (Near Approval)This treatment is in the last trial phase before FDA approval
Prior Safety DataThis treatment has passed at least one previous human trial
Trial Summary
What is the purpose of this trial?
A Multicenter, Randomized, Double-Masked, Sham-Controlled, Parallel-Group Phase 3 Study to Evaluate the Efficacy and Safety of Epithelium-On Corneal Cross-linking in Subjects 8 to 45 Years of Age With Keratoconus
Research Team
MB
Michael Belin, MD
Principal Investigator
Epion Therapeutics
Eligibility Criteria
Inclusion Criteria
You have been diagnosed with keratoconus.
Treatment Details
Participant Groups
2Treatment groups
Experimental Treatment
Placebo Group
Group I: Active TreatmentExperimental Treatment1 Intervention
Epithelium-on corneal cross-linking
Group II: Control TreatmentPlacebo Group1 Intervention
Placebo and sham for epithelium-on corneal cross-linking
Find a Clinic Near You
Who Is Running the Clinical Trial?
Epion Therapeutics
Lead Sponsor
Trials
2
Recruited
800+
Other People Viewed
By Subject
By Trial
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.